Delpazolid is under clinical development by LegoChem Biosciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Delpazolid’s likelihood of approval (LoA) and phase transition for Tuberculosis took place on 02 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Delpazolid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Delpazolid overview

Delpazolid (LCB-010371) is under development for the treatment of gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci infections, Streptococcus pneumoniae infections, multidrug-resistant tuberculosis infections and pulmonary tuberculosis. It is a next-generation oxazolidinone antibiotic administered through oral and intravenous route. It acts by targeting 23s ribosomal RNA.

LegoChem Biosciences overview

LegoChem Biosciences (LCB) focuses on the discovery and development of novel therapeutics for infectious diseases, oncology, and immuno-oncology indications. The company is investigating antibody-drug conjugates (ADC) to treat non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), triple-negative breast cancer (TNBC), myelodysplastic syndromes (MDS), and other solid and hematological cancers. It is also developing antibiotics for gram-negative and gram-positive bacterial infections; anti-fibrotic against non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases; and anticoagulants to treat coronary artery diseases and minimize the side effects of bleeding. LCB utilizes its ConjuAll and Legochemisty platform technologies to discover and develop drugs. The company works in partnership with pharmaceutical and biotechnology companies to discover new drugs. LCB is headquartered in Daejeon, South Korea.

Quick View Delpazolid LOA Data

Report Segments
  • Innovator
Drug Name
  • Delpazolid
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.